Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Fig. 1

Best Radiographic Response in Grade III Glioma Patients. BEV = bevacizumab. The X axis represents the number of doses of pembrolizumab that was received. The color represents the best radiographic response each patient had. 3 patients continue on pembrolizumab at the end of data collection. 6 patients previously progressed on bevacizumab; of those patients 5 continued bevacizumab with pembrolizumab. 4 patients never received bevacizumab, of those 1 started on bevacizumab with pembrolziumab. One patient had a partial response; 2 had stable disease; and the rest had progressive disease

Back to article page